deaths (OS)progression or deaths (PFS)RFS/DFS

malignant mesothelioma (mMS) - 1st line (L1) malignant mesothelioma (mMS) - 1st line (L1)

versus pemetrexed plus platin
nivolumab plus ipilimumab vs. pemetrexed plus platin 1 1.0better0.35.0100 %1.0better0.35.050 %-

malignant mesothelioma (mMS) - 2nd line (L2) malignant mesothelioma (mMS) - 2nd line (L2)